SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants Apr 22, 2022
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections Apr 22, 2022
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal Apr 20, 2022
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives Apr 19, 2022
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Mar 29, 2022
SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update Mar 24, 2022
